JP2017506626A5 - - Google Patents

Download PDF

Info

Publication number
JP2017506626A5
JP2017506626A5 JP2016550471A JP2016550471A JP2017506626A5 JP 2017506626 A5 JP2017506626 A5 JP 2017506626A5 JP 2016550471 A JP2016550471 A JP 2016550471A JP 2016550471 A JP2016550471 A JP 2016550471A JP 2017506626 A5 JP2017506626 A5 JP 2017506626A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
antibody
antigen
binding fragment
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016550471A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017506626A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/015633 external-priority patent/WO2015123423A2/en
Publication of JP2017506626A publication Critical patent/JP2017506626A/ja
Publication of JP2017506626A5 publication Critical patent/JP2017506626A5/ja
Pending legal-status Critical Current

Links

JP2016550471A 2014-02-14 2015-02-12 中程度用量スタチン療法により適切に管理されない高コレステロール血症を有する患者を処置するための方法 Pending JP2017506626A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201461939857P 2014-02-14 2014-02-14
US61/939,857 2014-02-14
US201462000162P 2014-05-19 2014-05-19
US62/000,162 2014-05-19
US201462025094P 2014-07-16 2014-07-16
US62/025,094 2014-07-16
US201462052227P 2014-09-18 2014-09-18
US62/052,227 2014-09-18
EP14306729 2014-10-29
EP14306729.6 2014-10-29
PCT/US2015/015633 WO2015123423A2 (en) 2014-02-14 2015-02-12 Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy

Publications (2)

Publication Number Publication Date
JP2017506626A JP2017506626A (ja) 2017-03-09
JP2017506626A5 true JP2017506626A5 (https=) 2018-03-15

Family

ID=51870958

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016550471A Pending JP2017506626A (ja) 2014-02-14 2015-02-12 中程度用量スタチン療法により適切に管理されない高コレステロール血症を有する患者を処置するための方法

Country Status (10)

Country Link
US (2) US20150231236A1 (https=)
EP (1) EP3104879A2 (https=)
JP (1) JP2017506626A (https=)
KR (1) KR20160115939A (https=)
CN (1) CN106029096A (https=)
AU (1) AU2015217118A1 (https=)
CA (1) CA2939507A1 (https=)
EA (1) EA201691320A1 (https=)
MX (1) MX2016010504A (https=)
WO (1) WO2015123423A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
PL3395836T3 (pl) 2011-01-28 2021-12-13 Sanofi Biotechnology Ludzkie przeciwciała przeciwko pcsk9 do zastosowania w sposobach leczenia konkretnych grup osobników
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
ES2992345T3 (es) 2011-09-16 2024-12-11 Regeneron Pharma Métodos para reducir los niveles de lipoproteína(a) mediante la administración de un inhibidor de la proproteína convertasa subtilisina kexina-9 (PCSK9)
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
US20140257473A1 (en) * 2012-10-22 2014-09-11 Nalini Marie Rajamannan Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis
US10058630B2 (en) 2012-10-22 2018-08-28 Concievalve, Llc Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TW202021614A (zh) 2013-06-07 2020-06-16 法商賽諾菲生物技術公司 藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法
MX2016006226A (es) 2013-11-12 2016-09-07 Sanofi Biotechnology Regimenes de dosificacion para uso con inhibidores de pcsk9.
EP3142645A4 (en) 2014-05-15 2017-12-27 Rani Therapeutics, LLC Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
US10689460B2 (en) * 2014-05-15 2020-06-23 Incube Labs, Llc PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US20230374155A1 (en) * 2014-05-15 2023-11-23 Rani Therapeutics, Llc Pcsk9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
AU2015289874A1 (en) * 2014-07-14 2017-02-02 Amgen Inc. Crystalline antibody formulations
PL3169353T3 (pl) 2014-07-16 2020-06-01 Sanofi Biotechnology SPOSOBY LECZENIA PACJENTÓW Z HETEROZYGOTYCZNĄ HIPERCHOLESTEROLEMIĄ RODZINNĄ (heFH)
JP2018523684A (ja) 2015-08-18 2018-08-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
WO2017044665A1 (en) 2015-09-08 2017-03-16 Mir Imran Pcsk9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US20170332139A1 (en) 2016-05-10 2017-11-16 Rovi Guides, Inc. System and method for delivering missed portions of media assets to interested viewers
US20190321515A1 (en) * 2016-06-27 2019-10-24 ConcieValve LLC Improved methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis
BR112019020148A2 (pt) 2017-04-13 2020-05-05 Cadila Healthcare Limited peptídeo
GB201720162D0 (en) 2017-12-04 2018-01-17 Univ Oxford Innovation Ltd Method
SG11202107614PA (en) 2019-01-18 2021-08-30 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
PL3395836T3 (pl) * 2011-01-28 2021-12-13 Sanofi Biotechnology Ludzkie przeciwciała przeciwko pcsk9 do zastosowania w sposobach leczenia konkretnych grup osobników
ES2992345T3 (es) * 2011-09-16 2024-12-11 Regeneron Pharma Métodos para reducir los niveles de lipoproteína(a) mediante la administración de un inhibidor de la proproteína convertasa subtilisina kexina-9 (PCSK9)
US9255154B2 (en) * 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
CA2874244A1 (en) * 2012-05-25 2013-11-28 Catabasis Pharmaceuticals, Inc. Methods of lowering proprotein convertase subtilisin/kexin type 9 (pcsk9)

Similar Documents

Publication Publication Date Title
JP2017506626A5 (https=)
JP2017528427A5 (https=)
JP7404471B2 (ja) 家族性高コレステロール血症を有する患者を処置するための方法
JP2016538248A5 (https=)
JP2016538277A5 (https=)
JP7744190B2 (ja) リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
JP2022141868A (ja) 心血管リスクを低減させる方法
JP2016522211A5 (https=)
JP2017522316A5 (https=)
JP2019514907A5 (https=)
JP2020002171A5 (https=)
JP2022177142A5 (https=)
JP2017509624A5 (https=)
IL277127B1 (en) Using pcsk9 tracking to reduce cardiovascular risk
JP2018523684A5 (https=)
RU2017104800A (ru) Способы лечения пациентов с гетерозиготной семейной гиперхолестеринемией (hefh)
RU2017104799A (ru) Способы лечения пациентов с высоким риском возникновения сердечно-сосудистых заболеваний, имеющих гиперхолестеринемию
JP2017503820A5 (https=)
JP2016529255A5 (https=)
KR102296017B1 (ko) 혈관 질환 및 이에 따른 합병증 치료
JP2014516953A5 (https=)
JP7541810B2 (ja) Ａｎｇｐｔｌ３阻害剤と組み合わせてｐｃｓｋ９阻害剤を投与することにより高脂血症を有する患者を処置するための方法
JP2020504110A5 (https=)
JP2015526458A5 (https=)
RU2017108173A (ru) Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1